RAPT Therapeutics (RAPT Therapeutics) FCF Margin % : 0.00% (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is RAPT Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. RAPT Therapeutics's Free Cash Flow for the three months ended in Mar. 2024 was $-27.19 Mil. RAPT Therapeutics's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, RAPT Therapeutics's FCF Margin % for the quarter that ended in Mar. 2024 was 0.00%.

As of today, RAPT Therapeutics's current FCF Yield % is -69.50%.

The historical rank and industry rank for RAPT Therapeutics's FCF Margin % or its related term are showing as below:

During the past 7 years, the highest FCF Margin % of RAPT Therapeutics was -810.97%. The lowest was -4689.98%. And the median was -1620.27%.

RAPT's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -143.92
* Ranked among companies with meaningful FCF Margin % only.

RAPT Therapeutics FCF Margin % Historical Data

The historical data trend for RAPT Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RAPT Therapeutics FCF Margin % Chart

RAPT Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-810.97

-1,620.27

-4,689.98

RAPT Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of RAPT Therapeutics's FCF Margin %

For the Biotechnology subindustry, RAPT Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

RAPT Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RAPT Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where RAPT Therapeutics's FCF Margin % falls into.

RAPT Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

RAPT Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-98.173	/	0
	=	%

RAPT Therapeutics's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-27.189	/	0
	=	%

RAPT Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of RAPT Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

RAPT Therapeutics (RAPT Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RAPT Therapeutics Inc (NAS:RAPT) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

0RA:Germany

Address

561 Eccles Avenue, South San Francisco, CA, USA, 94080

Website

https://www.rapt.com

RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.

Executives

Dirk G. Brockstedt	officer: Chief Scientific Officer	C/O ADURO BIOTECH, INC., 740 HEINZ AVENUE, BERKELEY CA 94710
William Ho	officer: Chief Medical Officer	561 ECCLES AVENUE, SOUTH SAN FRANCISCO CA 94080
Wendye Robbins	director	C/O RAPT THERAPEUTICS, INC., 561 ECCLES AVENUE, SOUTH SAN FRANCISCO CA 94080
Column Group Ii, Lp	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Tcg Iv Gp, Llc	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Iv Gp, Lp	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Iv, Lp	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Iv-a, Lp	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Rodney Kb Young	officer: Chief Financial Officer	STEMCELLS, INC., 3155 PORTER DRIVE, PALO ALTO CA 94304
Lori Lyons-williams	director	C/O DERMIRA, INC., 275 MIDDLEFIELD ROAD, SUITE 150, MENLO PARK CA 94025
Column Group Llc	10 percent owner	1 LETTERMAN DRIVE, BUILDING D, SUITE M-900, SAN FRANCISCO CA 94129
Ponoi Ii Management, Llc	10 percent owner	1 LETTERMAN DRIVE, BUILDING D, SUITE M-900, SAN FRANCISCO CA 94129
Ponoi Capital Ii, Lp	10 percent owner	1700 OWENS STREET, STE 500, SAN FRANCISCO CA 94158
Ponoi Management, Llc	10 percent owner	1 LETTERMAN DRIVE, BUILDING D, SUITE M-900, SAN FRANCISCO CA 94129
Ponoi Capital, Lp	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158